Search Results - "Abbate, Kelly"

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy by Saab, Karim R., Mooradian, Meghan J., Wang, Daniel Y., Chon, Jeewon, Xia, Cathy Y., Bialczak, Angelica, Abbate, Kelly T., Menzies, Alexander M., Johnson, Douglas B., Sullivan, Ryan J., Shoushtari, Alexander N.

“…Background Combined BRAF and MEK inhibition (BRAF‐MEK) is a standard therapy for patients with BRAF V600–mutant melanoma, but to the authors’ knowledge, the…”
Get full text

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma by Shoushtari, Alexander N, Ong, Leonard T, Schoder, Heiko, Singh-Kandah, Shahnaz, Abbate, Kelly T, Postow, Michael A, Callahan, Margaret K, Wolchok, Jedd, Chapman, Paul B, Panageas, Katherine S, Schwartz, Gary K, Carvajal, Richard D

“…The aim of this study was to test the hypothesis that inhibiting mammalian target of rapamycin and insulin-like growth factor-1 receptor would be efficacious…”
Get full text

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study by Najjar, Yana G, Navrazhina, Kristina, Ding, Fei, Bhatia, Roma, Tsai, Katy, Abbate, Kelly, Durden, Barbara, Eroglu, Zeynep, Bhatia, Shailender, Park, Song, Chowdhary, Akansha, Chandra, Sunandana, Kennedy, Jonathan, Ernstoff, Marc, Vachhani, Pankit, Drabick, Joseph, Singh, Arun, Xu, Tan, Yang, Jessica, Carvajal, Richard, Manson, Daniel, M Kirkwood, John, Cohen, Justine, Sullivan, Ryan, Johnson, Douglas, Funchain, Pauline, Shoushtari, Alexander

“…BackgroundUveal melanoma (UM) is the most common intraocular malignancy in adults. In contrast to cutaneous melanoma (CM), there is no standard therapy, and…”
Get full text

Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection by Zhang, Jennifer Q., Montagna, Giacomo, Sevilimedu, Varadan, Abbate, Kelly, Charyn, Jillian, Mehrara, Babak, Morrow, Monica, Barrio, Andrea V.

“…Background Patients often fear axillary lymph node dissection (ALND) because of its associated complications; however, its effect on quality of life (QOL) is…”
Get full text

Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancer-Related Lymphedema by Montagna, Giacomo, Zhang, Jennifer, Sevilimedu, Varadan, Charyn, Jillian, Abbate, Kelly, Gomez, Ethan A, Mehrara, Babak, Morrow, Monica, Barrio, Andrea V

“…Risk factors for breast cancer-related lymphedema (BCRL) after axillary lymph node dissection (ALND) are poorly understood. To evaluate rates of and risk…”
Get more information

Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype by Pawloski, Kate R., Wen, Hannah Y., Tadros, Audree B., Abbate, Kelly, Morrow, Monica, El-Tamer, Mahmoud

“…Background Among patients with multifocal or multicentric (MF/MC) breast cancer (BC) of similar morphology, concordance in Oncotype DX recurrence scores (RS)…”
Get full text

ASO Visual Abstract: Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection by Zhang, Jennifer Q., Montagna, Giacomo, Sevilimedu, Varadan, Abbate, Kelly, Charyn, Jillian, Mehrara, Babak, Morrow, Monica, Barrio, Andrea V.

Get full text

Statistical machine learning model to predict Oncotype DX risk category in women over age 50 by Pawloski, Kate R., Gonen, Mithat, Wen, Hannah Yong, Tadros, Audree B., Abbate, Kelly, Thompson, Donna, Morrow, Monica, El-Tamer, Mahmoud

“…Abstract only 524 Background: The 21-gene Oncotype DX Breast Recurrence Score multigene assay (RS) identifies women with ER positive, HER negative, axillary…”
Get full text

Supervised machine learning model to predict oncotype DX risk category in patients over age 50 by Pawloski, Kate R., Gonen, Mithat, Wen, Hannah Y., Tadros, Audree B., Thompson, Donna, Abbate, Kelly, Morrow, Monica, El-Tamer, Mahmoud

“…Purpose Routine use of the oncotype DX recurrence score (RS) in patients with early-stage, estrogen receptor-positive, HER2-negative (ER+/HER2−) breast cancer…”
Get full text

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma by Shoushtari, Alexander N, Khan, Shaheer, Komatsubara, Kimberly, Feun, Lynn, Acquavella, Nicolas, Singh-Kandah, Shahnaz, Negri, Tiffany, Nesson, Alexandra, Abbate, Kelly, Cremers, Serge, Musi, Elgilda, Ambrosini, Grazia, Lee, Shing, Schwartz, Gary K, Carvajal, Richard D

“…Uveal melanoma (UM) is a rare subset of melanoma characterized by the presence of early initiating GNAQ/11 mutations, with downstream activation of the PKC,…”
Get full text

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy by Saab, Karim, Mooradian, Meghan, Wang, Daniel Ying, Chon, Jeewon, Xia, Cathy Yi, Bialczak, Angelica, Abbate, Kelly, Menzies, Alexander M., Johnson, Douglas Buckner, Sullivan, Ryan J., Shoushtari, Alexander Noor

“…Abstract only…”
Get full text